Science behind phase I clinical trials: targeting tumour cell development pathways

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013

ASCO 2013 highlights

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
ASCO 2013 highlights ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013

Crizotinib superior to chemo for advanced ALK positive NSCLC

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Crizotinib superior to chemo for advanced ALK positive NSCLC ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
6 Jun 2013

Comment on progression free survival in lung cancer patients and the GALAXY-1 trial

Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA
Comment on progression free survival in lung cancer patients and the GALAXY-1 trial ( Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA )
3 Jun 2013

Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
3 Jun 2013

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
3 Jun 2013

Nivolumab blocking PD1 in lung cancer and melanoma

Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA
Nivolumab blocking PD1 in lung cancer and melanoma ( Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA )
3 Jun 2013

Crizotinib and molecular testing in advanced non small cell lung cancer

Dr Fred Hirsch - University of Colorado, Denver, USA
Crizotinib and molecular testing in advanced non small cell lung cancer ( Dr Fred Hirsch - University of Colorado, Denver, USA )
3 Jun 2013

Nintedanib in combination with standard second line therapy in lung cancer

Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany
Nintedanib in combination with standard second line therapy in lung cancer ( Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany )
3 Jun 2013

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
3 Jun 2013

New targets for squamos cell carcinoma

Dr Martin Reck – Hospital Grosshansdorf, Wohrendamm, Germany
New targets for squamos cell carcinoma ( Dr Martin Reck – Hospital Grosshansdorf, Wohrendamm, Germany )
16 May 2013

Surgery in mesothelioma

Dr Paul Baas - Netherlands Cancer Institute, Amsterdam
Surgery in mesothelioma ( Dr Paul Baas - Netherlands Cancer Institute, Amsterdam )
16 May 2013